IDEXX Laboratories (IDXX) vs Myriad Genetics (MYGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
IDEXX Laboratories (IDXX) has outperformed Myriad Genetics (MYGN) over the past year, losing 17.6% versus a loss of 44.3%. Over five years, IDXX leads with a -18.4% price change compared with -86.4% for MYGN. IDEXX Laboratories is the larger company by market cap ($40.81 billion vs $412.2 million), about 99.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IDXX | MYGN |
|---|---|---|
| Share price | $518.00 | $4.31 |
| Market cap | $40.81B | $412.25M |
| 1-day change | +0.95% | +2.62% |
| YTD return | -23.43% | -29.92% |
| 1-year return | -17.61% | -44.32% |
| 5-year return | -18.44% | -86.42% |
| P/E ratio (TTM) | 36.40 | — |
| Forward P/E | 30.95 | — |
| EPS (TTM) | $14.23 | $-1.18 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $4.30B | — |
| Revenue growth (YoY) | +10.42% | — |
| Net income (latest FY) | $1.06B | — |
| Gross margin | 61.80% | — |
| Operating margin | 31.60% | — |
| Net margin | 24.62% | — |
| 52-week high | $769.98 | $8.59 |
| 52-week low | $500.61 | $2.74 |
| Distance from 52-week high | -32.73% | -49.83% |
| Analyst consensus | buy | hold |
| Avg. price target upside | +35.39% | -9.28% |
| Average volume | 553.95K | 2.04M |
| Shares outstanding | 78.78M | 95.65M |
| Employees | 11,000 | 2,700 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IDEXX Laboratories is about 99.0 times larger than Myriad Genetics by market value ($40.81B vs $412.25M).
- IDXX has outperformed MYGN by 26.7 percentage points over the past year.
About IDEXX Laboratories
IDXX stock →IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 11,000 employees
About Myriad Genetics
MYGN stock →Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 2,700 employees
IDXX vs MYGN FAQ
Which is bigger, IDEXX Laboratories or Myriad Genetics?
IDEXX Laboratories (IDXX) is larger, with a market capitalization of $40.81B compared with $412.25M for Myriad Genetics (MYGN).
Which stock has performed better over the past year, IDXX or MYGN?
IDXX returned -17.61% over the past 12 months, compared with -44.32% for MYGN (price return, excluding dividends). Past performance does not predict future results.
Are IDEXX Laboratories and Myriad Genetics in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.